Experience of the anti-inflammatory eye drops Ivinak®-SOLOpharm use in patients after cataract surgery

Abstract

BACKGROUND: The prevalence of inflammatory complications that occur after phacoemulsification remains an unsolved problem.
 AIM: To analyze the results of the use of Ivinak-SOLOpharm eye drops containing 0.09% bromfenac solution in the complex of anti-inflammatory therapy in patients after cataract surgery in comparison with similar drugs from other manufacturers.
 MATERIALS AND METHODS: The study included 60 patients (60 eyes) with a diagnosis of age-related cataract, who underwent phacoemulsification. All patients were divided into 2 groups: in the first group, patients used Ivinac eye drops 3 days before surgery and 20 days after it; in the second group, patients used another similar drug containing 0.09% bromfenac solution according to an identical scheme. All patients underwent visual acuity testing and keratopachimetry before and after surgery. On Day 4 and Day 20 after surgery, the degree of inflammatory reaction of the eye was assessed by the number of cells in the anterior chamber fluid, subjective signs of inflammation in patients, using the OSDI (Ocular Surface Disease Index) questionnaire.
 RESULTS: When analyzing the obtained data, no statistically significant differences were found between the groups in terms of best corrected visual acuity, corneal thickness, number of cells in the anterior chamber fluid, and subjective symptoms of inflammation in patients.
 CONCLUSIONS: Ivinak-SOLOpharm has proven its effectiveness and safety in the perioperative prevention of inflammatory processes in phacoemulsification.